QuickView: Potential of LymPro indicated
Amarantus presented data of its blood-based diagnostic test for Alzheimer’s disease (AD), LymPro, at the Alzheimer’s Association International Conference (AAIC). Data from a 41-patient trial with an optimised test showed a specificity of 81% and a sensitivity of 73%. Commercial launch of LymPro as a laboratory-developed test remains on track for H214. MANF has also started formal preclinical testing and could begin clinical development in 2015. Eltoprazine is expected to start a Phase IIb trial in the coming months.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.